$ Value
$0
Shares
69,355
Price
$0
Filed
Apr 22
Insider
Name
Faga Daniel
Title
President, CEO
CIK
0001673528
Roles
Transaction Details
Transaction Date
2026-04-20
Code
A
Table
Derivative
Ownership
Direct
Equity Swap
No
Shares After
69,355
Footnotes
Consists of shares of common stock received in connection with the spin-off of First Tracks Biotherapeutics, Inc. ("First Tracks") from AnaptysBio, Inc. ("AnaptysBio"). | Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement. | The stock option is fully vested and exercisable. | The stock option vests as to 25% of the total shares on January 6, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. | The stock option vests as to 25% of the total shares on January 3, 2025, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. | The stock option vests as to 25% of the total shares on January 7, 2026, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. | The stock option vests as to 25% of the total shares on January 6, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. | Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. | Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation Agreement, each outstanding restricted stock unit ("RSU") with respect to AnaptysBio shares of common stock was adjusted so that such RSU became an RSU with respect to First Tracks shares of common stock and an RSU with respect to AnaptysBio's shares of common stock. As a result, the Reporting Person acquired RSUs with respect to First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement. | The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. | The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. | The RSUs vests as to 25% of the total RSUs annually commencing on January 7, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. | The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2027 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Filing Info
Faga Daniel's History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2026-04-20 | ANAB | A | $0 |
| 2026-04-20 | ANAB | D | $0 |
| 2026-04-20 | ANAB | A | $0 |
| 2026-04-20 | ANAB | D | $0 |
| 2026-04-20 | ANAB | A | $0 |
| 2026-04-20 | ANAB | D | $0 |
| 2026-04-20 | ANAB | A | $0 |
| 2026-04-20 | ANAB | D | $0 |
| 2026-04-20 | ANAB | A | $0 |
| 2026-04-20 | ANAB | D | $0 |
Other Insiders at TRAX (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
| FENTON DENNIS M | — | — | 2026-04-20 |
| ANAPTYSBIO, INC | — | — | 2026-04-20 |
| Orwin John A | — | — | 2026-04-20 |
| Schmid John P. | — | — | 2026-04-20 |
| EcoR1 Capital, LLC | — | $65.0M | 2026-04-20 |
| Marquet Magda | — | — | 2026-04-20 |
|
Faga Daniel
President, CEO
|
— | — | 2026-04-20 |
| Jain Rita | — | — | 2026-04-20 |
|
Lizzul Paul F.
Chief Medical Officer
|
— | — | 2026-04-20 |
| Ware J. Anthony | — | — | 2026-04-20 |
|
Tamboli Ajim
Chief Financial Officer
|
— | — | 2026-04-23 |